PCI Pharma Capacity Update October 2024: Small Molecule

In the October 2024 edition of the Outsourced Pharma Capacity Update, PCI’s Rob Jones highlights how recent strategic investments have significantly expanded capacity for the development, manufacturing, and packaging of highly potent drug products, including both solid oral and liquid dosage forms.

These advancements build on PCI’s 35+ years of expertise in handling potent drug compounds and leverage the success of the UK site’s original Contained Manufacturing Facility (CMF), which has been a trusted resource since its launch in 2013. With these enhancements, PCI is better equipped than ever to meet the growing demand for high-containment manufacturing solutions, supporting a wide range of complex pharmaceutical projects.